Shares of Eli Lilly & Co. LLY advanced 2.48% to $733.29 Thursday, on what proved to be an all-around great trading session ...

The major U.S. equities indexes were mixed at midday Thursday, with the Dow Jones Industrial Average down close to 400 points ...

Eli Lilly surges 11% on strong phase-three trial data for its weight-loss and diabetes pill, boosting healthcare sentiment. S&P Futures Rebound While Dow Struggles On UnitedHealth Collapse Daily E ...

While broader market trends showed an upward trajectory with the Dow Jones and S&P 500 also rising, Eli Lilly’s comprehensive ...

Eli Lilly revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio. The drug maker logged net income of $2.76 billion, or $3.06 a share, up ...

Eli Lilly said its Zepbound obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk's Wegovy in a head-to-head study of the two drugs.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... In contrast, the Dow Jones fell by 1.33 percent, and the Nasdaq dropped by 0.13 percent.

Sources: FactSet, Dow Jones Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet ...

Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 1132 ET – Novo Nordisk’s American depositary receipts fall sharply after U.S. rival Eli Lilly said an ...

Eli Lilly revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio. The drug maker logged net income of $2.76 billion, or $3.06 a share ...